Teclistamab治疗抗CD19 CAR-T失败后复发性多重难治性获得性血友病A
一例复发性获得性血友病A患者,既往多线免疫抑制治疗及自体抗CD19嵌合抗原受体T细胞治疗均失败,后接受teclistamab(靶向CD3与BCMA的双特异性单抗)治疗。治疗耐受良好,除低丙种球蛋白血症外无临床显著不良事件,迅速获得持久缓解并持续超过1年。这是首例难治性获得性血友病A经teclistamab成功治疗的报道,为浆细胞导向的双特异性抗体提供了概念验证。
要点
- Teclistamab可用于多线治疗及抗CD19 CAR-T失败的难治性获得性血友病A。
- 治疗耐受良好,除低丙种球蛋白血症外无临床显著不良事件。
- 迅速获得持久缓解,持续超过1年。
核心结论
- Teclistamab在抗CD19 CAR-T治疗失败后的复发性多重难治性获得性血友病A中诱导了迅速且持久的缓解,持续超过1年。
研究设计与样本
- 单例病例报告:患者为复发性获得性血友病A,既往多线免疫抑制治疗及自体抗CD19 CAR-T治疗失败。
主要发现
- Teclistamab耐受良好,除低丙种球蛋白血症外无临床显著不良事件。
- 治疗后迅速获得持久缓解,持续超过1年。
临床怎么用
- 提示浆细胞导向的双特异性抗体可作为难治性获得性血友病A的潜在治疗选择,支持进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A patient with relapsed acquired hemophilia A (AHA), who previously failed multiple lines of immunosuppressive therapy, including autologous anti-CD19 chimeric antigen receptor cell therapy, received teclistamab, a bispecific monoclonal antibody engaging autologous CD3-positive T cells with the B cell maturation antigen on plasma cells and mature B cells. Teclistamab was well tolerated without clinically significant adverse events, except for hypogammaglobulinemia. Prompt and durable remission was observed that lasted for more than 1 year posttreatment. This is the first case of refractory acquired hemophilia A successfully treated with teclistamab, providing a proof-of-concept for plasma cell-directed bispecific antibodies and supporting their further evaluation.
引用
- Dobbelstein CE, Stoyanov K, Aleksandrova K, et al. Teclistamab in relapsed, multirefractory acquired hemophilia A after failure of anti-CD19 chimeric antigen receptor T-cell therapy. J Thromb Haemost. 2026. PMID: 42785443. doi:10.1016/j.jtha.2026.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。